Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy

• DOI: 10.1016/j.tem.2023.05.003
• Publication Date: 2023-05-26T20:19:46Z
• Authors: Huachun Pan; Shumin Yang; Wenke Cheng; Qiang Cai; Quazi T.H. Shubhra
• Keywords: Cardiotoxicity

Doxorubicin (Dox) is a highly potent chemotherapy drug. Despite its efficacy, Dox's clinical application is limited due to its association with significant complications, namely cardiotoxicity and the risk of heart failure. Recent intriguing findings by Ozcan et al. indicate that alternate-day fasting (ADF) significantly exacerbates the cardiotoxicity of Dox.